Today begins a new chapter for GRAIL as an independent, publicly traded company. We will be listed under $GRAL on Nasdaq as of the market open June 25. Learn more: https://bit.ly/3S4T1H9
GRAIL
Biotechnology Research
Menlo Park, CA 87,082 followers
Detect cancer early, when it can be cured.
About us
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit grail.com. Community Guidelines: https://bit.ly/3xigb24
- Website
-
http://www.grail.com
External link for GRAIL
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Menlo Park, CA
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Cancer Detection, Cancer Biology, Clinical Trials, Computer Science, Machine Learning, and Data Science
Locations
-
Primary
1525 O'Brien Drive
Menlo Park, CA 94025, US
Employees at GRAIL
Updates
-
JCO Precision Oncology has published our findings that clinical utility of our multi-cancer early detection (MCED) test preferentially detects a cancer signal in the presence of high-grade (aggressive) and high stage, clinically significant prostate cancer over slow-growing cases. This analysis reinforces the potential of MCED to minimize the overdiagnosis of prostate cases that may not need treatment. Learn more about the data: https://bit.ly/3TafgvI Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a cancer signal detected result which includes predicted Cancer Signal Origin(s). After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis. The overall sensitivity in study participants with prostate cancer was 11.2% (3.2% for stage I, 4.9% stage II, 14.0% stage III, 83.3% stage IV).
-
-
After facing cancer, Tami became a passionate advocate for early screening. She and her family joined GRAIL’s PATHFINDER study on multi-cancer early detection (MCED) testing. Tami shares her experiences with cancer and MCED testing: https://bit.ly/4dxhYDH
-
Keith is a retiree with an engineering background who loves understanding how things work. He was eager to speak to his healthcare provider about multi-cancer early detection testing (MCED). Keith shares his experiences – and why he finds the possibilities of MCED so exciting – in this video: https://bit.ly/3L6ZUUf
-
Today GRAIL reported Q2 2024 financial results. Read more: https://bit.ly/3M38DqT
-
-
In randomized controlled trials (RCTs) of #cancer screening, late-stage cancer incidence may function as an early surrogate for mortality. A new review of 33 RCTs finds a strong linear association between late-stage cancer incidence and mortality, offering a potential alternative endpoint that could provide useful results in less time. Read more here: https://lnkd.in/g4w3n4NN
-
-
Welcome Susanna Quinn – the new host of The Cancer SIGNAL podcast! https://bit.ly/3WBF18V Susanna, an ovarian cancer survivor and advocate, is passionate about GRAIL’s mission of detecting cancer early, when it can be cured. To introduce us, the Cancer SIGNAL’s inaugural host Kim Thiboldeaux interviews Susanna about her cancer story and how it’s shaped her outlook on life and health.
-
Proactive screening plays a vital role in detecting #LungCancer and other cancers early, when they are often easier to treat. This #WorldLungCancerDay, learn more about the screening guidelines and some of the available tools from American Cancer Society: https://bit.ly/3WkaLiU
-
-
We will issue financial results for the second quarter 2024 on Tuesday, August 13, 2024. Register for the live teleconference on https://bit.ly/3SynZr7. See more details: https://bit.ly/3Yr28FJ
-